ImmunityBio: Forging A New Plan After Recent $100 Million Offering

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been a little more than two months since my last ImmunityBio (NASDAQ: IBRX ) article , where I discussed ANKTIVA's commercial launch for BCG-unresponsive non-muscle invasive bladder cancer. I believed ImmunityBio's commercial strategy, along with ...